SAN DIEGO, February 4 /PRNewswire/ --

- Deal follows positive phase I data from novel product candidate AM103 for the oral treatment of respiratory disease

Amira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein ) inhibitors for the treatment of respiratory and cardiovascular disease.

RALEIGH, North Carolina, February 4 /PRNewswire/ --

DARA BioSciences, Inc. today announced that the Company will present at the ROTH 20th Annual Growth Stock Conference in Dana Point, CA on Tuesday, February 19, 2008 at 3:30pm Pacific.

Interested parties can access a live web cast of the presentation at www.darabiosciences.com. A replay of the presentation will be available at the same location.

About DARA BioSciences, Inc.

WARRINGTON, England, February 4 /PRNewswire/ --

- dise3G transformed into diseMP: MultiPlay for total convergence

Martin Dawes Systems, an international provider of billing, customer care and business assurance solutions for the communications market, today announced diseMP (MultiPlay), the latest enhanced version of its widely used subscriber management platform, which was previously known as dise3G.

PARIS, February 4 /PRNewswire/ -- A Working Group of representatives from seven international health-care organizations call for improved blood pressure (BP) goal rate levels of patients with hypertension, the single most important cause of attributable mortality around the world. This has driven the working group to identify 5 specific concrete practical actions which are described in the January 2008 issue of the Journal of Human Hypertension(1): Detect and Prevent high BP; Assess total cardiovascular risk; Form an active partnership with the patient; Treat hypertension to goal; Create a supportive environment.

HONG KONG, February 4 /PRNewswire/ --

- Maximizing Shareholder Interests Optimizing Future Development

One of the leading game developers and operators in the PRC, NetDragon Websoft Inc. ("NetDragon" or the "Company", with its subsidiary collectively the "Group"; Stock Code: 8288.HK) is pleased to announce that it has bought back 271,000 of its shares on 31 January 2008.

The total number of shares bought back up to 31 January 2008 now amounts to 4,276,000 shares, and the total amount paid is about HK$56,493,900 at prices of between HK$12.40 and HK$14.48 per share.

DÜSSELDORF, Germany, February 4 /PRNewswire/ --

- Sales up by 48% at EUR958 Million - EBITDA Margin Reaches High Level of 19%

- Another Acquisition in the Target Segment of Pharmaceutical Plastics in South America: Brazilian Market Leader for Pharma Plastic Taken Over

According to provisional figures, Gerresheimer AG has just completed another record year. In 2007 the company achieved sales of EUR957.7m, up by 48.1%; the adjusted Group EBITDA margin reached 19%. "This gratifying development completely and fully confirms our strategy," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG: "With the help of acquisitions we have successfully expanded our global presence and set the course for further growth."